Free Trial
→ The Iran War Isn’t Chaos. It’s Strategy. (From Behind the Markets) (Ad)tc pixel Free AARD Stock Alerts

Aardvark Therapeutics (AARD) Competitors

Aardvark Therapeutics logo
$3.92 -0.12 (-2.97%)
As of 02:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

AARD vs. GLAS, CGC, FENC, ENTA, and TTRX

Should you buy Aardvark Therapeutics stock or one of its competitors? Aardvark Therapeutics's main competitors and comparable companies include Glass House Brands (GLAS), Canopy Growth (CGC), Adherex Technologies (FENC), Enanta Pharmaceuticals (ENTA), and Turn Therapeutics (TTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aardvark Therapeutics compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Aardvark Therapeutics has a net margin of 0.00% compared to Glass House Brands' net margin of -31.68%. Glass House Brands' return on equity of -60.92% beat Aardvark Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Glass House Brands-31.68% -60.92% -15.69%
Aardvark Therapeutics N/A -71.54%-64.94%

Glass House Brands presently has a consensus target price of $16.00, indicating a potential upside of 318.41%. Aardvark Therapeutics has a consensus target price of $13.13, indicating a potential upside of 224.88%. Given Glass House Brands' higher probable upside, equities research analysts clearly believe Glass House Brands is more favorable than Aardvark Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Glass House Brands
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aardvark Therapeutics
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36

In the previous week, Aardvark Therapeutics had 24 more articles in the media than Glass House Brands. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 2 mentions for Glass House Brands. Glass House Brands' average media sentiment score of 0.19 beat Aardvark Therapeutics' score of 0.14 indicating that Glass House Brands is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Glass House Brands
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aardvark Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
19 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Glass House Brands has higher revenue and earnings than Aardvark Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Glass House Brands$181.98M1.95-$29.66MN/AN/A
Aardvark TherapeuticsN/AN/A-$57.59M-$3.21N/A

Summary

Glass House Brands beats Aardvark Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Canopy Growth?

Aardvark Therapeutics (NASDAQ:AARD) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Aardvark Therapeutics has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aardvark TherapeuticsN/AN/A-$57.59M-$3.21N/A
Canopy Growth$251.01M1.36-$190.29M-$0.45N/A

Aardvark Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Aardvark Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aardvark TherapeuticsN/A -71.54% -64.94%
Canopy Growth -65.33%-21.91%-14.34%

Aardvark Therapeutics has a beta of 3.8, indicating that its share price is 280% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Aardvark Therapeutics presently has a consensus price target of $13.13, indicating a potential upside of 224.88%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aardvark Therapeutics
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36
Canopy Growth
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

3.3% of Canopy Growth shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Aardvark Therapeutics had 18 more articles in the media than Canopy Growth. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 8 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.98 beat Aardvark Therapeutics' score of 0.14 indicating that Canopy Growth is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aardvark Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
19 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Canopy Growth
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Aardvark Therapeutics beats Canopy Growth on 10 of the 16 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Adherex Technologies?

Aardvark Therapeutics (NASDAQ:AARD) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Aardvark Therapeutics has a beta of 3.8, suggesting that its share price is 280% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 25 more articles in the media than Adherex Technologies. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 1 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 1.82 beat Aardvark Therapeutics' score of 0.14 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Aardvark Therapeutics Neutral
Adherex Technologies Very Positive

Aardvark Therapeutics currently has a consensus target price of $13.13, suggesting a potential upside of 224.88%. Adherex Technologies has a consensus target price of $17.00, suggesting a potential upside of 66.99%. Given Aardvark Therapeutics' higher possible upside, equities analysts clearly believe Aardvark Therapeutics is more favorable than Adherex Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aardvark Therapeutics
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36
Adherex Technologies
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Aardvark Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -5.71% beat Aardvark Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aardvark TherapeuticsN/A -71.54% -64.94%
Adherex Technologies -6.09%-5.71%-2.37%

55.5% of Adherex Technologies shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Adherex Technologies has higher revenue and earnings than Aardvark Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aardvark TherapeuticsN/AN/A-$57.59M-$3.21N/A
Adherex Technologies$44.64M8.01-$9.74M-$0.13N/A

Summary

Adherex Technologies beats Aardvark Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aardvark Therapeutics had 22 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 4 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.22 beat Aardvark Therapeutics' score of 0.14 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enanta Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aardvark Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
19 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aardvark Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enanta Pharmaceuticals$65.32M5.14-$81.89M-$2.41N/A
Aardvark TherapeuticsN/AN/A-$57.59M-$3.21N/A

Aardvark Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Enanta Pharmaceuticals' return on equity of -61.84% beat Aardvark Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enanta Pharmaceuticals-96.89% -61.84% -20.70%
Aardvark Therapeutics N/A -71.54%-64.94%

Enanta Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.8, indicating that its stock price is 280% more volatile than the broader market.

Enanta Pharmaceuticals currently has a consensus price target of $19.00, suggesting a potential upside of 64.93%. Aardvark Therapeutics has a consensus price target of $13.13, suggesting a potential upside of 224.88%. Given Aardvark Therapeutics' higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Enanta Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enanta Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Aardvark Therapeutics
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36

Summary

Aardvark Therapeutics beats Enanta Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Aardvark Therapeutics' return on equity of -71.54% beat Turn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Turn TherapeuticsN/A -230.84% -53.19%
Aardvark Therapeutics N/A -71.54%-64.94%

Turn Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Turn TherapeuticsN/AN/A-$3.19M-$0.29N/A
Aardvark TherapeuticsN/AN/A-$57.59M-$3.21N/A

Turn Therapeutics presently has a consensus target price of $9.00, suggesting a potential downside of 15.09%. Aardvark Therapeutics has a consensus target price of $13.13, suggesting a potential upside of 224.88%. Given Aardvark Therapeutics' higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Turn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Turn Therapeutics
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.50
Aardvark Therapeutics
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36

In the previous week, Aardvark Therapeutics had 18 more articles in the media than Turn Therapeutics. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 8 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.34 beat Aardvark Therapeutics' score of 0.14 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Turn Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aardvark Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
19 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Turn Therapeutics beats Aardvark Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AARD vs. The Competition

Export
MetricAardvark TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$85.22M$12.42B$7.27B$12.97B
Dividend YieldN/A2.63%2.51%22.89%
P/E Ratio-1.21807.81275.4025.37
Price / SalesN/A748.45562.2978.82
Price / CashN/A86.6577.1653.04
Price / Book0.799.2110.555.95
Net Income-$57.59M$2.84B$3.50B$380.75M
7 Day Performance-21.47%-4.00%-3.92%-3.96%
1 Month Performance-29.82%-8.07%-8.30%-6.81%
1 Year Performance-73.77%-5.86%2.35%-4.58%

Aardvark Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AARD
Aardvark Therapeutics
3.1895 of 5 stars		$3.92
-3.0%		$13.13
+234.8%		-72.4%$85.22MN/AN/A28
GLAS
Glass House Brands
2.3769 of 5 stars		$4.27
-3.2%		$16.00
+274.8%		N/A$409.04M$181.98MN/A357
CGC
Canopy Growth
1.194 of 5 stars		$0.83
-2.3%		N/A-44.3%$380.47M$251.01MN/A1,128
FENC
Adherex Technologies
4.4786 of 5 stars		$10.71
+0.8%		$17.00
+58.7%		+20.6%$373.52M$44.64MN/A35
ENTA
Enanta Pharmaceuticals
2.1121 of 5 stars		$12.50
+3.3%		$19.00
+52.0%		+0.3%$364.06M$65.26MN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AARD) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
Microscopic footage reveals immune cells destroying cancer cells
Time-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...
Market Tactic | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Elon pays this company. Every time.
Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...
Behind the Markets | Sponsoredtc pixel
Elon will prove them wrong again
Elon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no ...
Paradigm Press | Sponsoredtc pixel